Dr. Ludlam is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
550 17th Ave
Ste 500
Seattle, WA 98122Phone+1 206-320-2800Fax+1 206-320-3153
Education & Training
Oregon Health & Science University (OHSU Health)Fellowship, Endocrinology, Diabetes, and Metabolism, 1997 - 1999- Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 1995 - 1997
Albert Einstein College of MedicineClass of 1995
Certifications & Licensure
OR State Medical License 1998 - Present
WA State Medical License 2007 - 2025
Clinical Trials
- An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Start of enrollment: 2011 Aug 16
Publications & Presentations
PubMed
- 50 citationsDelayed postoperative hyponatremia after transsphenoidal surgery: prevalence and associated factors.Namath S. Hussain, Mackenzie Piper, W Grant Ludlam, William H. Ludlam, Cindy J. Fuller
Journal of Neurosurgery. 2013-12-01 - 105 citationsRoute of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults.David M. Cook, William H. Ludlam, Marie B. Cook
The Journal of Clinical Endocrinology and Metabolism. 1999-11-01 - 205 citationsTreatment of Pituitary-Dependent Cushing’s Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II TrialMarco Boscaro, William H. Ludlam, B. Atkinson, J. E. Glusman, Stephan Petersenn
The Journal of Clinical Endocrinology and Metabolism. 2009-01-01
Press Mentions
AstraZeneca Promotes Oncology Exec to CMO; Pfizer Replaces Retiring Chief Dealmaker as War Chest ExpandsAugust 27th, 2021- Chutes & Ladders—Pfizer Taps McKinsey U.S. Managing Partner as New M&a LeaderAugust 27th, 2021
- Recordati Rare Diseases Announces William Ludlam, MD, PhD, as New Chief Medical Officer and Vice President - Clinical DevelopmentAugust 25th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
